Aura Biosciences Inc (AURA)

Several events have impacted Aura Biosciences, Inc. (AURA) stock price in the past six months. Aura Biosciences announced and closed a public offering of common stock and pre-funded warrants, raising $299 million but resulting in material dilution. Natalie Holles was appointed as President and a member of the Board of Directors, succeeding Elisabet de los Pinos. Aura Biosciences reported its fourth quarter and full year 2025 financial results, with an EPS of -$0.37, beating expectations, and provided updates on the CoMpass and NMIBC trials. The company reported its third quarter 2025 financial results, updating guidance for the CoMpass trial and presenting immune profiling data for bel-sar in bladder cancer. Insider Elisabet de los Pinos sold 47,648 shares of the company's stock. Aura Biosciences' stock has increased by 53.5% since the start of 2026, reaching a new 52-week high of $9.54 in early May 2026.

Traditional demand seasonality is not directly applicable to Aura Biosciences' products and services. The demand for its therapies is driven by the incidence of specific cancer types, the progress of its clinical trials, regulatory approvals, and the medical community's adoption of new treatments upon commercialization. While the stock price itself has shown some seasonality, this reflects investor sentiment and market dynamics rather than product demand.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors, particularly for preserving organ function. The company operates within the Healthcare sector, specifically in Biotechnology, Drug Discovery, and Oncology, utilizing its Virus-Like Drug Conjugate (VDC) technology platform. Their lead product candidate, belzupacap sarotalocan (bel-sar), is in late-stage clinical development for primary choroidal melanoma and early-stage development for other ocular oncology indications and non-muscle invasive bladder cancer (NMIBC).

Aura Biosciences, Inc. is headquartered in Boston, Massachusetts, United States. The company's operations are primarily focused in the United States, with plans to expand into European markets by 2026 to address unmet medical needs in oncology. Clinical trial enrollment for bel-sar is actively global, with increasing momentum observed in both the United States and the European Union.

Aura Biosciences has been covered in the media for 11 events in the past year, with a focus on company updates and people movement. The company's reputation is tied to the progress and outcomes of its clinical trials, regulatory designations, and financial stability. Positive announcements regarding clinical data and successful public offerings contribute positively to its reputation, while delays in clinical trials or negative trial outcomes could impact it negatively.

Aura Biosciences, Inc. is primarily owned by institutional shareholders, who hold 78.31% of the company's stock, while insiders own 15.28%, and retail investors hold 6.41%. Major institutional owners include Matrix Capital Management Company, LP, Frazier Life Sciences Management, L.P., and Adage Capital Partners Gp, L.l.c. Matrix Capital Management Company LP is the largest individual shareholder, owning 6.92 million shares, representing 10.79% of the company.